Imaging metastatic bone disease from carcinoma of the prostate

British Journal of Cancer

Volumn 101, Issue 8, 2009, Pages 1225-1232

  Messiou, C ^a   Cook, G ^b   Desouza, N M ^a  

^a INSTITUTE OF CANCER RESEARCH   (United Kingdom)

^b INSTITUTE OF CANCER RESEARCH   (United Kingdom)

Author keywords

Diagnostic imaging; Neoplasm metastasis; Prostatic neoplasms

Indexed keywords

ACETIC ACID C 11; CHOLINE C 11; CHOLINE F 18; FLUORODEOXYGLUCOSE F 18; GLUCOSE; MEDRONATE TECHNETIUM TC 99M; PROSTATE SPECIFIC ANTIGEN; RADIOISOTOPE; UNCLASSIFIED DRUG;

ANTIANDROGEN THERAPY; BENIGN TUMOR; BONE MARROW METASTASIS; BONE METASTASIS; BONE SCINTISCANNING; CANCER CELL; CANCER DIAGNOSIS; CELL ACTIVITY; COMPUTER ASSISTED EMISSION TOMOGRAPHY; COMPUTER ASSISTED TOMOGRAPHY; DIFFERENTIAL DIAGNOSIS; DIFFUSION WEIGHTED IMAGING; DRUG ACCUMULATION; DRUG EXCRETION; DRUG HALF LIFE; FOLLOW UP; GLUCOSE METABOLISM; GLUCOSE TRANSPORT; GLYCOLYSIS; HUMAN; MALIGNANT NEOPLASTIC DISEASE; NUCLEAR MAGNETIC RESONANCE IMAGING; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; OSTEOBLAST; OSTEOCLAST; OSTEOLYSIS; PATHOLOGICAL ANATOMY; PHOSPHORUS NUCLEAR MAGNETIC RESONANCE; PREDICTIVE VALIDITY; PRIORITY JOURNAL; PROGNOSIS; PROSTATE CARCINOMA; PROTON NUCLEAR MAGNETIC RESONANCE; SENSITIVITY AND SPECIFICITY; SHORT SURVEY; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; TRABECULAR BONE; TREATMENT RESPONSE;

BONE AND BONES; BONE NEOPLASMS; FLUORODEOXYGLUCOSE F18; HUMANS; MAGNETIC RESONANCE IMAGING; MALE; POSITRON-EMISSION TOMOGRAPHY; PROSTATIC NEOPLASMS; TOMOGRAPHY, X-RAY COMPUTED;

EID: 70349971472     PISSN: 00070920     EISSN: 15321827     Source Type: Journal    
DOI: 10.1038/sj.bjc.6605334     Document Type: Short Survey

References (39)

1. Algra PR, Bloem J, Tissing H, Falke TH, Arndt JW, Verboom LJ (1991) Detection of vertebral metastases: comparison between MR imaging and bone scintigraphy. Radiographics 11: 219-232
2. Apolo A, Pandit-Taskar N, Morriss MJ (2008) Novel tracers and their development for the imaging of metastatic prostate cancer. J Nucl Med 49: 2031-2041
3. Beheshti M, Vali R, Waldenberger P, Fitz F, Nader M, Loidl W, Broinger G, Stoiber F, Foglman I, Langsteger W (2008) Detection of bone metastases in patients with prostate cancer by 18F fluorocholine and 18 F fluoride PET-CT: a comparative study. Eur J Nucl Med Mol Imaging 35: 1766-1774
4. Bubendorf L, Schopfer A, Wagner U, Sauter G, Moch H, Wili N, Gasser TC, Mihatsch MJ (2000) Metastatic patterns of prostate cancer: an autopsy study of 1589 patients. Hum Path 31: 578-583
5. Carlin BI, Andriole GL (2000) The natural history, skeletal complications and management of bone metastases in patients with prostate carcinoma. Cancer 88: 2989-2994
6. Charles-Edwards EM, deSouza NM (2006) Diffusion-weighted magnetic resonance imaging and its application to cancer. Cancer Imaging 16: 135-143
7. Cheville JC, Tindall D, Boelter C, Jenkins R, Lohse CM, Pankratz VS, Sebo TJ, Davis B, Blute ML (2002) Metastatic prostate carcinoma to bone. Cancer 95: 1028-1036
8. Ciray I, Astrom G, Andreasson I, Edekling T, Hansen J, Bergh J, Ahlstrom H (2000) Evaluation of new sclerotic bone metastases in breast cancer patients during treatment. Acta Rad 41(2): 178-182
9. Clamp A, Danson S, Nguyen H, Cole D, Clemons M (2004) Assessment of therapeutic response in patients with metastatic bone disease. Lancet Oncol 5: 607-616
10. Coombes RC, Dady P, Parsons C, McCready VR, Ford HT, Gazet JC, Powles TJ (1983) Assessment of response of bone metastases to systemic treatment in patients with breast cancer. Cancer 52: 610-614
11. Cooper RC, Chay CH, Gendernalik JD, Lee HL, Bhatia J, Taichmen RS, McCauley LK, Keller ET, Pienta KJ (2003) Stromal factors involved in prostate carcinoma metastasis to bone. Cancer 97(3): 739-747
12. Eisenhauer EA, Therasses P, Bogaerts J, Schwartz LH, Sargent D, Ford R, Dancey J, Arbuck S, Gwyther S, Mooney M, Rubinstein L, Shankar L, Dodd L, Kaplan R, Lacombe D, Verweij J (2009) New response evaluation criteria in solid tumours: revised RECIST guideline. Eu J Cancer 45(2): 228-247
13. Even-Sapir E, Metser U, Mishani E, Mishani E, Lievshitz G, Lerman H, Leibovitch I (2006) The detection of bone metastases in patients with high risk prostate cancer: 99mTc-MDP planar bone scintigraphy, single and multi field of view SPECT, 18F-fluoride PET and 18F-fluoride PET/ CT. J Nuc Med 47: 287-297
14. Fogelman I, Cook G, Israel O, Van der Wall H (2005) Positron emission tomography and bone metastases. Semin Nucl Med 35: 135-142
15. Hara T, Kosaka N, Kishi H (1998) PET imaging of prostate cancer using carbon-11-choline. J Nuc Med 39: 990-995
16. Imbriaco M, Larson SM, Yeung HW, Mawlawi OR, Erdi Y, Venkatraman ES, Scher HI (1998) A new parameter for measuring metastatic bone involvement by prostate cancer: the bone scan index. Clin Cancer Res 4: 1765-1772
17. Kzerke J, Prang J, Neumaier B, Volkmer B, Guhlmann A, Kleinschmidt K, Hautmann R, Reske SN (2000) Experience with carbon-11 choline positron emission tomography in prostate carcinoma. Eur J Nuc Med 27(9): 1415-1419
18. Langsteger W, Hainisch M, Fogelman I (2006) The role of fluorodeox-yglucose, 18F-dihyroxyphenylalanine, 18F-choline and 18F-fluoride in bone imaging with emphasis on prostate and breast. Sem Nuc Med 36: 73-92
19. Lecouvet FE, Geukens D, Stainier A, Jamar J, d'Othee BJ, Therasses P, Vande Berg B, Tombal B (2007) Magnetic resonance imaging of the axial skeleton for detecting bone metastases in patients with high-risk prostate cancer: diagnostic and cost-effectiveness and comparison with current detection strategies. J Clin Onc 25: 3281-3287
20. Levenson RM, Sauerbrunn BJ, Bates HR, Newman RD, Eddy JL, Ihde DC (1983) Comparative value of bone scintigraphy and radiography in monitoring tumour response in systemically treated prostatic carcinoma. Radiology 146: 513-518
21. Luboldt W, Kufer R, Blumstein N, Toussaint TL, Kluge A, Seemann MD, Luboldt HJ (2008) Prostate carcinoma: diffusion weighted imaging as potential alternative to conventional MR and 11C-choline PET/CT for detection of bone metastases. Radiology 249: 1017-1025
22. Montemurro F, Russo F, Martinicich L, Cirillo S, Gatti M, Aqlieta M, Regge D (2004) Dynamic contrast enhanced magnetic resonance imaging in monitoring bone metastases in breast cancer patients receiving bispho-sphonates and endocrine therapy. Acta Rad 45: 71-74
23. Morris MJ, Akhurst T, Larson S, Ditullio M, Chu E, Siedlecki K, Verbel D, Heller G, Kelly K, Slovin S, Schwartz L, Scher HI (2005) Fluorodeox-yglucose positron emission tomography as an outcome measure for castrate metastatic prostate cancer treated with antimicrotubule chemotherapy. Clin Cancer Res 11(9): 3210-3216
24. Morris MJ, Akhurst T, Osman I, Nunez R, Macapinlac H, Siedlecki K, Verbel D, Schwartz L, Larson SM, Scher HI (2002) Fluorinated deoxyglucose positron emission tomography imaging in progressive metastatic prostate cancer. Urology 59: 913-918
25. Noguchi M, Kikuchi H, Ishibashi M, Noda S (2003) Percentage of the positive area of bone metastasis is an independent predictor of disease death in advanced prostate cancer. Br J Cancer 88: 195-201
26. Oyama N, Akino H, Kanamuru H, Saikawa S, Moriyama N, Oyama N, Akino H, Okada K, Yokoyama O (2002) 11C acetate PET imaging of prostate cancer. J Nucl Med 43: 181-186
27. Pollen JJ, Witztum KF, Ashburn WL (1984) The flare phenomenon on radionuclide bone scan in metastatic prostate cancer. Am J Roentgenol 142: 773-776
28. Ruckle HC, Klee GG, Oesterling JE (1994) Prostate-specific antigen: concepts for staging prostate cancer and monitoring response to therapy. Mayo Clin Proc 69(1): 69-79
29. Sabbatini P, Larson SM, Kremer A (1999) Prognostic significance of extent of disease in bone in patients with androgen-independent prostate cancer. J Clin Oncol 17: 948-957
30. Scher H (2003) Prostate carcinoma: defining therapeutic objectives and improving overall outcomes. Cancer Suppl 97: 758-771
31. Schneider A, Kalikin LM, Mattos AC, Keller ET, Allen MJ, Pienta KJ, McCauley LK (2005) Bone turnover mediates preferential localization of prostate cancer in the skeleton. Endocrinology 146: 1727-1736
32. Shreve PD, Grossman HB, Gross MD, Wahl RL (1996) Metastatic prostate cancer: initial findings of PET with 2-deoxy-2-[F-18]fluoro-D-glucose. Radiology 199: 751-756
33. Sijens PE, Van den Bent MJ, Oudkerk M (1997) Phosphorus-31 chemical shift imaging of metastatic tumors located in the spine region. Invest Rad 32: 344-350
34. Taira A, Herfkens RJ, Gambhir SS, Quon A (2007) Detection of bone metastases: assessment of integrated FDG PET/CT imaging. Radiology 243: 204-211
35. Taoka T, Mayr NA, Lee HJ, Yuh WT, Simonson TM, Rezai K, Berbaum KS (2001) Factors influencing visualisation of vertebral metastases on MR imaging versus bone scintigraphy. Am J Roentgenol 176: 1525-1530
36. Tombal B, Rezazadeh A, Therasse P, Van Cangh PJ, Vande Berg B, Lecouvet FE (2005) Magnetic resonance imaging of the axial skeleton enables objective measurement of tumour response on prostate cancer bone metastases. Prostate 65: 178-187
37. Tuncel M, Souvatzoglou M, Herrmann K, Stollfuss J, Schuster T, Weirich G, Wester HJ, Schwaiger M, Krause BJ (2008) 11C choline positron emission tomography/computed tomography for staging and restaging of patients with advanced prostate cancer. Nuc Med Biol 35: 689-695
38. Wang CK, Li CW, Hsieh TJ, Chien SH, Liu GC, Tsai KB (2004) Characterisation of bone and soft tissue tumours with in vivo 1H MR spectroscopy: initial results. Radiology 232: 599-605
39. Yamaguchi T, Tamai K, Yamato M, Honma K, Ueda Y, Saotome K (1996) Intertrabecular pattern of tumours metastatic to bone. Cancer 78: 1388-1394